DAX24.029 +1,2%Est505.972 +1,1%MSCI World4.343 -0,1%Top 10 Crypto9,5900 +1,2%Nas23.184 +1,2%Bitcoin63.176 -0,3%Euro1,1801 +0,4%Öl97,59 -0,4%Gold4.790 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Deutsche Telekom 555750 Rheinmetall 703000 SAP 716460 Lufthansa 823212 Siemens Energy ENER6Y NVIDIA 918422 BASF BASF11 Microsoft 870747 Mercedes-Benz Group (ex Daimler) 710000 Amazon 906866 Allianz 840400 Deutsche Bank 514000 DroneShield A2DMAA Infineon 623100 BioNTech (ADRs) A2PSR2
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Hoffnung im Iran-Konflikt: DAX um 24.000 Punkte -- Dow im Plus erwartet -- Novo Nordisk und OpenAI kooperieren -- JP Morgan, Citi, Intel, Sandisk, Tesla, SAP, Rüstungsaktien, Kryptos, Oracle im Fokus
Top News
UBS bleibt bullish: Warum die Goldpreis-Schwäche der Großbank zufolge eine Chance ist UBS bleibt bullish: Warum die Goldpreis-Schwäche der Großbank zufolge eine Chance ist
Pivotal-Point Nachverfolgung Lindblad Expeditions Holdings (LIND): Rekordnachfrage nach Luxus-Abenteuern - National Geographic Partner auf Wachstumskurs! Pivotal-Point Nachverfolgung Lindblad Expeditions Holdings (LIND): Rekordnachfrage nach Luxus-Abenteuern - National Geographic Partner auf Wachstumskurs!
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Spyre Therapeutics Aktie

Kaufen
Verkaufen
53,50 EUR +10,10 EUR +23,27 %
FSE
52,00 EUR -2,00 EUR -3,70 %
HAML
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.3,43 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3D4LY

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00773J2024

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSYRE

Spyre Therapeutics Aktien News

DatumMeistgelesen
PR NewswireSpyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
PR NewswireSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on ...
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics to Participate in Upcoming June Investor Conferences
PR NewswireSpyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics to Participate in Upcoming March Investor Conferences
PR NewswireSpyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Added to the Nasdaq Biotechnology Index
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
PR NewswireSpyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disea...
PR NewswireSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment ...
PR NewswireSpyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics to Participate in Upcoming November Investor Conferences
PR NewswireSpyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combin...
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
PR NewswireSpyre Therapeutics to Participate in Upcoming Investor Conference
PR NewswireSpyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
PR NewswireSpyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
PR NewswireSpyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics News

Spyre Therapeutics News: auf dieser Seite finden Sie alle Spyre Therapeutics News und Nachrichten zur Spyre Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Spyre Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Spyre Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.